$PFSA

HRT FINANCIAL LP purchased $1K of PFSA

HRT FINANCIAL LP purchased 1,310 shares of Profusa, Inc. (PFSA) at $1.01 on 2026-07-29.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jul 30, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PFSA
Bullish
medium confidence
Mentioned
$PFSA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFSABullishLow
01

Why it matters

The newest fact is the specific open-market purchase: 1,310 shares at $1.0100, totaling $1,323.10, with post-transaction holdings of 83,871 shares.

02

Market read

Traders may note the 10% owner buying, but the disclosed transaction value is small and lacks fundamental follow-through in the text.

03

What to watch

No 10b5-1 plan is cited, but the filing also provides no rationale, and the dollar value is too small to infer conviction about near-term fundamentals.

Relevance 4/10Novelty 3/10Timing: filed 2026-07-30, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Profusa, Inc. (PFSA).

Company-level read

Ticker impact

$PFSABullishMedium confidence
Context

Profusa, Inc. (PFSA) disclosed an insider Form 4 showing HRT Financial LP bought 1,310 shares at $1.01 on 2026-07-29.

Expected impact

Likely limited near-term impact; any effect would be incremental sentiment rather than a re-rating catalyst.

Evidence & confidence

The filing is primary-source and specific, but the transaction size ($1,323) is small and there is no accompanying guidance, deal, or operational change.

Market effects

No clear sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

A small open-market add by a 10% owner may reflect routine liquidity management or diversification rather than a strong bullish thesis.

Key entities

  • Profusa, Inc.

    Subject of the Form 4 insider transaction disclosure (PFSA).

  • HRT Financial LP

    Reporter and 10% owner who purchased shares via open-market purchase code P.

  • SEC Form 4

    Primary-source insider transaction report filed on 2026-07-30.

Related articles

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.